|
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
J. Biol. Chem., Vol. 279, Issue 42, 44123-44132, October 15, 2004
Induction of Genes Mediating Interferon-dependent Extracellular Trap Formation during Neutrophil Differentiation*![]() ![]() ![]() ![]() **![]()
From the
Received for publication, May 26, 2004 , and in revised form, July 16, 2004.
Interferons (IFNs) are cytokines that possess potent anti-viral and immunoregulatory activities. In contrast, their potential role(s) in anti-bacterial defense and neutrophil activation mechanisms is less well explored. By comparing gene expression patterns between immature and mature human neutrophils, we obtained evidence that intracellular proteases and other anti-bacterial proteins are produced at earlier stages of maturation, whereas the genes for receptors and signaling molecules required for the release of these effector molecules are preferentially induced during terminal differentiation. For instance, mature neutrophils strongly expressed genes that increase their responses to type I and type II IFNs. Interestingly, granulocyte/macrophage colony-stimulating factor was identified as a repressor of IFN signaling components and consequently of IFN-responsive genes. Both IFN- and IFN- induced strong tyrosine phosphorylation of STAT1 in mature but not in immature neutrophils. Functional in vitro studies suggested that IFNs act as priming factors on mature neutrophils, allowing the formation of extracellular traps upon subsequent stimulation with complement factor 5a (C5a). In contrast, both IFN- and IFN- had only little capacity to prime immature cells in this system. Moreover, both IFNs did not have significant anti-proliferative effects on immature neutrophils. These data contribute to our understanding regarding changes of gene expression during neutrophil differentiation and IFN-mediated anti-bacterial defense mechanisms.
Neutrophils are a critical component of the innate immune system with several effector and immunoregulatory functions (1). They are generated in the bone marrow under the influence of cytokines, such as granulocyte colony-stimulating factor (G-CSF)1 and granulocyte/macrophage colony-stimulating factor (GM-CSF), from hematopoietic stem cells. Interestingly, G-CSF is not expressed in normal bone marrow cells under physiologic conditions (2), suggesting that it drives myeloid differentiation in a hormonal manner. Multiple cell types such as endothelial cells, epithelial cells, fibroblasts, and macrophages are able to produce G-CSF and GM-CSF (3, 4). All these cells make early contact with invading microorganisms and/or their products, resulting in increased cytokine production after infection. For instance, blood G-CSF levels have been described to rise from 25 to up to 10,000 pg/ml under pathologic conditions (5). Moreover, systemic injection of G-CSF (6) or GM-CSF (7) results in a dramatic increase of neutrophil production. Taken together, G-CSF and GM-CSF have been demonstrated to be major regulators of neutrophil production. Under conditions of stress, such as infections, neutrophil numbers in blood can increase as a consequence of cytokine-forced neutrophil differentiation.
Although immature neutrophils can be classified by morphology as well as by the expression of more or less specific surface proteins (8), it is difficult to obtain pure cell populations characterized by a certain maturation stage. Therefore, most of the studies trying to understand neutrophil differentiation at the molecular level were performed by using cell lines derived from leukemias. Previously published work resulted in the identification of genes that may play critical roles in the differentiation of neutrophils (9). Moreover, a gene expression profile of neutrophils has been established (10). Despite these previous studies, the underlying molecular events of normal neutrophil differentiation are not well understood, and many of the genes that are expressed by mature neutrophils have not been related to function. The objective of this study was to compare the transcriptional repertoire of immature and mature human neutrophils by using oligonucleotide microarrays. In addition we investigated whether certain differences in gene expression are reversible by in vitro re-exposure of mature neutrophils with GM-CSF. Although multiple genes were more expressed in mature compared with immature cells, it was interesting to see that mature neutrophils also demonstrated higher expression of genes, which transduce signals of type I and type II interferons. Consequently, several known IFN-responsive genes had elevated expression levels in mature compared with immature cells. The subsequently obtained functional data demonstrate the importance of increased IFN sensitivity of mature neutrophils for the formation of extracellular traps, which consist of antimicrobial agents able to kill bacteria (11).
ReagentsHuman IFN- was purchased from PBL Biomedical Laboratories (Alexis Corp., Lausen, Switzerland), and human IFN- was from R&D Systems (Abingdon, United Kingdom). Human GM-CSF was from Novartis Pharma GmbH (Nürnberg, Germany), and human GCSF was from Aventis Pharma AG (Zurich, Switzerland). Complement factor 5a (C5a) was from Calbiochem. Fluorescein-conjugated anti-CD14 and anti-CD15 and allophycocyanin-conjugated anti-CD34 and anti-CD11b as well as phycoerythrin-conjugated anti-CD7, anti-CD16, and anti-CD36 monoclonal antibodies (mAbs) were obtained from BD Biosciences). Anti-STAT1 and anti-phospho-STAT1 (Y701) rabbit polyclonal Abs were from Cell Signaling Technology, Inc. (Bioconcept, Allschwill, Switzerland). Anti-STAT2, anti-Jak1, anti-Jak2, and anti-IFNABR-1 rabbit polyclonal Abs were from Santa Cruz Biotechnology, Inc. (LabForce AG, Nunningen, Switzerland). We obtained the following rabbit polyclonal antibodies from Fitzgerald Industries International, Inc. (Concord, MA: anti-IFNABR-2 (anti-CD118), anti-IFNGR-1 (anti-CD119), and anti-IFNGR-2 (anti-CD119). Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mAb was ordered from Chemicon International, Inc. (Temecula, CA). Horseradish peroxidase-conjugated secondary Ab was purchased from Amersham Biosciences. Horseradish peroxidase-conjugated goat anti-rabbit IgG, Fc -specific, was obtained from Jackson ImmunoResearch Laboratories, Milan Analytika, La Roche, Switzerland). Anti-phycoerythrin secondary Abs microbeads were from Miltenyi Biotec GmbH (Bergisch Gladbach, Germany). Phytohemagglutinin was from Roche Diagnostics. Propidium iodide and Sytox Orange were both obtained from Molecular Probes (distributed by Invitrogen). Unless stated otherwise, all other reagents were from Sigma. CellsImmature neutrophils were isolated from bone marrow aspirates with normal cellular morphology and distribution as previously described (12). Briefly, after centrifugation on a two-step discontinuous Percoll density gradient, cells were negatively isolated using anti-CD7 and anti-CD36 mAbs to eliminate contaminating lymphoid and erythroid precursors. The resulting cell population contained >97% cells of the neutrophil lineage as determined by MPO staining and analysis of lineage-associated surface proteins as well as with Diff-Quik (Medion GmbH, Düdingen, Switzerland) and light microscopy. Table I demonstrates the distribution of the different maturation stages within the immature neutrophil populations used in this study. On average we counted 15% myeloblasts, 14% promyelocytes, 36% myelocytes, 30% metamyelocytes and band cells, and 5% mature bone marrow neutrophils.
Mature peripheral blood neutrophils and peripheral blood mononuclear cells (PBMC) were purified from healthy normal individuals by Ficoll-Hypaque centrifugation (4, 13). The resulting cell populations contained less than 5% contaminating cells. Eosinophil contamination was always less than 2%. Written informed consent was obtained from all patients and control individuals who donated bone marrow aspirates and blood, respectively. The study was approved by the ethics committee of the Canton Bern.
Cell CulturesHuman immature and mature neutrophils were cultured at 1 x 106/ml in complete culture medium (RPMI 1640 containing 10% fetal calf serum) in the presence and absence of GM-CSF (50 ng/ml), G-CSF (25 ng/ml), IFN-
Gene Expression ProfilingTotal RNA was isolated using the TRIzol reagent (Invitrogen). Double-stranded cDNA was generated using a Superscript cDNA synthesis kit (Invitrogen) using an oligo(dT)24 primer containing a T7 RNA polymerase promoter at the 3' end (Microsynth, Balgach, Switzerland). Labeled cRNA was prepared from double-stranded cDNA by in vitro transcription using a T7 polymerase (MEGAscript T7 kit, Ambion (Europe) Ltd., Huntingdon, UK) in the presence of biotin-11-CTP and biotin-16-UTP (Enzo Diagnostics, Farmingdale, NY) and purified using RNeasy columns (Qiagen AG, Basle, Switzerland). 15 µg of biotinylated cRNA were fragmented and hybridized to HG-U95Av2 GeneChip® arrays (Affymetrix, Santa Clara, CA) which contain probe sets representing After scanning of the probe arrays, digitalized image data were processed using Affymetrix Microarray Suite 5.0 software. In addition to determining the expression level for each gene (so called "signal"), this software assigns a "detection" call, absent (A) (not expressed), present (P) (expressed) and marginal (M) (marginally expressed) for each gene measured. The overall fluorescence intensity was scaled to a global intensity of 500 to enable the comparison between chips. Gene Array Data AnalysisThe expression data for all genes were exported to GeneSpring 5.0 (Silicon Genetics, Redwood City, CA). The following criteria were used to select differentially expressed genes in immature versus mature neutrophils or in GM-CSF-treated versus not treated neutrophils: 1) Student's t test with a multiple testing correction (Benjamini-Hochberg) significance level p < 0.05; 2) fold-change cut-off of 4 (2 for GM-CSF treatment) in both directions; 3) the P calls had to coincide with the regulation in question, e.g. if a candidate gene were to be called "up-regulated" in mature (GM-CSF treated cells), triplicate samples in the "treated" group had to be called P, and vice versa, if a gene were to be called "down-regulated," triplicate samples in the immature (untreated) group had to have a P call. The selected differentially expressed genes were normalized to a mean of 0 and a S.D. of 1, log2-transformed, and subjected to average-linkage hierarchical clustering using the uncentered Pearson similarity matrix (14). Clustering analysis was performed using the GENE CLUSTER program, and the figures were generated with TREE VIEW program (14) (rana.lbl.gov). The selected genes were annotated using the NetAffx analysis system offered by Affymetrix (15). Real-time PCRApproximately 1 µg of total RNA was reverse-transcribed using oligo-p(dT)15 priming and avian myeloblastosis virus reverse transcriptase (1st strand cDNA synthesis kit for reverse transcription-PCR, Roche Applied Science GmbH) at 42 °C for 1 h. PCR amplifications were carried out using HotStart system (LightCycler Faststart DNA Master SYBR Green I, Roche Applied Science) on the LightCyclerTM thermocycler as previously described (16). Primer sets used and cycling conditions are shown in Table II. PCR reactions were run in triplicate. Plasmids with IFNABR-1 and IFNABR-2 as well as IFNGR-1 and IFNGR-2 inserts were kindly provided by Dr. Silvio Hemmi, Dept. of Molecular Biology, University of Zurich, Zurich, Switzerland. Plasmids with STAT1, STAT2, Jak1, and Jak2 inserts were kind gifts from Dr. Timothy Hoey, Tularik Inc., San Francisco, CA. Serially diluted plasmids with corresponding gene inserts were used to generate the standard curve and subsequently used to calculate the number of the target molecules per sample. Results were initially expressed as the absolute copy number/µl. To compensate the variations in quantity and quality of starting mRNA, the absolute gene copy numbers/µl were normalized by the absolute GAPDH mRNA copy number/µl.
Gel Electrophoresis and ImmunoblottingCells (1-2.5 x 106) were washed with phosphate-buffered saline and lysed with modified radioimmune precipitation assay buffer (0.25% sodium deoxycholate, 1% Nonidet P-40, 150 mM sodium chloride, 50 mM Tris, pH 7.4) supplemented with a protease inhibitor mixture (Sigma) and 10 µM phenylmethylsulfonyl fluoride (Roche Applied Science) on ice for 30 min (17, 18). For phospho-STAT1 immunoblots, radioimmune precipitation assay buffer was used, which contained 1% Triton X-100. After a 10-min centrifugation to remove insoluble particles, loading buffer was added, and equal amounts of the cell lysates were loaded on NuPage gels (Invitrogen). Separated proteins were electrotransferred onto polyvinylidene difluoride membranes (Immobilon-P, Millipore, Volketswil, Switzerland) except for phospho-STAT1 immunoblots where we used Hybound-ECL nitrocellulose membranes (Amersham Biosciences). The filters were incubated overnight with anti-IFNABR-1 (1/500), anti-IFNABR-2 (1/2000), anti-IFNGR-1 (1/3000), anti-IFNGR-2 (1/1000), anti-Jak1 (1/500), anti-Jak2 (1/500), anti-STAT1 (1/1000), and anti-STAT2 (1/1000) Abs at 4 °C in Tris-buffered saline, 0.1% Tween 20, 3% nonfat dry milk. Anti-phospho-STAT1 Ab was diluted in 1% bovine serum albumin (essentially globulin-free, Sigma (A-7638)), Tris-buffered saline, 0.1% Tween 20 (1/1000). The final concentrations of the primary Abs ranged between 0.3 and 0.5 µg/ml. For loading controls stripped filters were incubated with anti-GAPDH (1/2000) mAbs. Filters were washed in Tris-buffered saline, 0.1% Tween 20 for 30 min and incubated with the appropriate horseradish peroxidase-conjugated secondary Ab in Tris-buffered saline, 0.1% Tween 20, 5% nonfat dry milk for 1 h. In the immunoprecipitation experiments blots were incubated with a horseradish peroxidase-conjugated secondary Ab recognizing the Fc fragment of the primary Ab only. Filters were developed by an ECL technique (ECL-Kit, Amersham Biosciences) according to the manufacturer's instructions.
[32P]Phosphorylation of STAT1Cells (2 x 107/ml) were preincubated for 2 h in phosphate-free medium (136 mM NaCl, 5.9 mM KCl, 1.2 mM MgSO4, 5.0 mM NaHCO3, 5.5 mM glucose, and 20 mM HEPES, pH 7.4) supplemented with 1 mCi/ml [32P]orthophosphate (Amersham Biosciences). Cells were washed and stimulated with IFN-
Analysis of Neutrophil Extracellular TrapsMature and immature neutrophils were seeded on poly-L-lysine 12-mm glass (BD Biosciences), allowed to settle, and then either primed with IFN- To quantify DNA release, neutrophils were seeded into 96-well plates (Greiner Bio-One GmbH, Frickenhausen, Germany) and stimulated under the same conditions as described above. Five µM Sytox Orange, a non cell-permeable DNA binding dye, was added (11). The plates were read using the imaging system Typhoon 9200 using a filter setting of 532 nm (excitation)/580 nm (emission) and TotalLab software (Amersham Biosciences). In addition, plates were analyzed by light microscopy and photographed. For MPO release analysis the same protocol for cell activation was used. Released MPO was measured in the supernatants by spectroscopy (20). Briefly, 10 µl of supernatant and 10 µl of 20 mg/ml o-dianisidine were added to 155 µl of 100 mM potassium phosphate buffer, pH 6.0, containing 0.5% hexadecyltrimethylammonium bromide. The reaction was started by adding 25 µl of 2 mM hydrogen peroxide solution. Absorbance of 450 nm of visible light was measured at 37 °C for 20-30 min. MPO concentrations were calculated using an MPO standard.
Proliferation AssayProliferation of immature neutrophils was induced by GM-CSF or G-CSF in complete culture medium. As control PBMC were stimulated with 10 µg/ml phytohemagglutinin. These proliferation assays were carried out in the presence and absence of interferons (IFN- Statistical AnalysisBesides the gene array data, results are expressed either as single data (usually triplicate experiments) or as the means ± S.E. for the indicated number of independent experiments. Student's t test was used to identify statistical significant differences. The calculated p values are indicated in the figures.
Differentially Expressed Genes in Immature Versus Mature Human NeutrophilsTo gain an understanding of the molecular processes that occur during differentiation and infection in neutrophils, we screened 12,599 genes for changes in gene expression using the following neutrophil populations: 1) immature neutrophils isolated from bone marrow aspirates, 2) mature neutrophils isolated from peripheral blood, and 3) mature neutrophils stimulated in vitro with GM-CSF for 7 h. Based on our filtering criteria, we identified 1049 genes that were differentially transcribed in immature and mature neutrophils (459 genes up-regulated and 590 down-regulated in immature cells). To facilitate further analysis, each gene was assigned to a defined functional category according to available annotations (NetAffx). As shown in Table III, immature neutrophils showed preferential expression of genes involved in protein biosynthesis, metabolism, and transcriptional control as well as in cell cycle, mitosis, and proliferation. In contrast, mature neutrophils appeared to up-regulate genes that regulate signal transduction, inflammatory responses, transcription, and apoptosis.
A detailed analysis of neutrophil lineage-associated genes suggested high mRNA expression of azurocidin 1, neutrophil elastase 2, bactericidal/permeability-increasing protein, lipocalin 2, MPO, cathepsin G, and neutrophil collagenase as well as the defensins 3 and 4 in immature neutrophils. In contrast, the transcriptional activity of mature neutrophils apparently switched to particularly produce receptors for antibodies, chemokines, and cytokines (Table IV). As expected, CD16, a transcript associated with later stages of neutrophil differentiation, was relatively more abundant in mature as compared with immature neutrophils. In contrast, CD33, a marker of immature cells, was indeed much higher expressed in immature compared with terminally differentiated neutrophils (data not shown).
Increased Expression of IFN Signaling and IFN-regulated Genes in Mature Compared with Immature Human NeutrophilsTwo-way unsupervised hierarchical clustering analysis, a mathematical approach that essentially organizes the data by grouping genes with similar expression pattern, yielded two major array clusters (i.e. immature and mature neutrophils) with this set of 1049 differentially expressed genes. In the analysis shown in Fig. 1 all the indicated genes were highly expressed in mature compared with immature neutrophils. Many of these genes are known to be regulated by IFN (22). Other genes with an apparently similar expression pattern encode proteins involved in multiple cellular functions, including adhesion, signal transduction, and apoptosis. Fig. 2A demonstrates a quantitative analysis of the induction of the IFN-regulated genes (up to 70-fold) in mature as compared with immature neutrophils.
Some of these genes are activated in response to type I IFNs (IFIT1, IFIT2, IFIT4, 2'-5' OASL, MxB protein), whereas others are induced by type II IFNs (GBP2, IP-30) or both (IFITM1-3). Furthermore, we observed the up-regulation of genes involved in type I (IFNABR-2, Jak1, STAT1, p48) and type II (IFNGR-1, IFNGR-2, Jak1, STAT1) IFN signaling pathways. Additional genes were higher expressed in mature compared with immature neutrophils that have also been shown to be induced by IFNs. For instance, we observed increases of caspase-1 (9.6-fold) and Pim-1 (5.5-fold) expressions as previously reported in IFN- -stimulated PBMC (23). Similarly, we found increases in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression (17.3-fold) in blood neutrophils, confirming recently published work obtained in IFN- -stimulated melanoma cells (24). Together, these data strongly suggest the activation of IFN-inducible genes during terminal neutrophil maturation. Interestingly, when we stimulated mature neutrophils with GM-CSF, a known growth factor of immature neutrophils, we observed that the expression of many of the IFN-regulated genes declined (Fig. 2B). This suggests that the induction of these genes in neutrophils may occur as a consequence of decreased GM-CSF exposure during terminal differentiation and/or following the bone marrow exit into the circulation. Because proximal and more distal elements of the IFN-signaling pathways are among these genes, it is possible that the transcript changes of the IFN-responsive genes reflect different in vivo efficacies in IFN signaling in immature and mature neutrophils. Over all, the gene expression responses of mature neutrophils toward GM-CSF revealed that 234 genes were up-regulated, and 414 were down-regulated. We used LightCyclerTM real-time PCR to verify changes in expression detected by microarray analysis (Fig. 3). We selected eight genes known to be important for type I and type II IFN signal transduction. There was a good correlation between real-time PCR data and microarray gene expression profiles. In particular, there was not a single difference in gene expression observed by using microarray analysis that could not be confirmed by the PCR technique. Because of the higher sensitivity of the LightCyclerTM PCR, additional gene expression differences were detected that have not been seen by microarray analysis. For instance, Jak2 and IFNABR-1 were not found to be repressed in immature cells compared with mature cells using the microarray analysis (Fig. 2A and 3). In addition, we found decreased expression of IFNGR-2 and IFNABR-2 in GMCSF-stimulated mature neutrophils compared with unstimulated mature neutrophils (Fig. 2B and 3). Taken together, microarray gene expression analysis seems to be highly specific but less sensitive as compared with real-time PCR measurements.
To investigate whether the observed differences in mRNA expression also result in differences in protein expression, we performed immunoblot analysis. As shown in Fig. 4, the protein expression analysis largely confirmed the microarray and LightCyclerTM gene expression data. Expression of Jak1, Jak2, and STAT1 was clearly increased in mature compared with immature neutrophils. Two IFN receptors (IFNABR-1 and IFNGR-1) were also more expressed in the mature cells. The differences in IFNABR-2 expression were less pronounced. The protein expression of IFNGR-2 did not appear to differ between mature and immature neutrophils. STAT2 expression in immature neutrophil populations varied between low expression and normal levels when compared with mature neutrophils.
IFN Signaling Is Accelerated in Mature Compared with Immature Human NeutrophilsThe different expression of some IFN receptors and the Jak kinases in immature and mature neutrophils implied that the two cell populations differentially transduce type I and type II IFN signals. To estimate the efficacy of IFN signaling, we measured the phosphorylation of Tyr-701 on STAT1 upon stimulation with type I and type II IFNs in both immature and mature neutrophils (25). As shown in Fig. 5A, both IFN- and IFN- increased tyrosine phosphorylation of STAT1 within 15 min of stimulation in mature neutrophils. In contrast, both IFNs induced no or only very weak responses in immature cells, and clear increases in tyrosine phosphorylation of STAT1 were also not evident at later time points. To exclude the possibility that equal increases in phosphorylation of STAT1 occurred in both neutrophil populations but were not detectable in immature neutrophils due to very low STAT1 levels, we immunoprecipitated STAT1 after 32P-labeling of the cells. This allowed loading of larger concentrations of STAT1 on the gels, most likely resulting in a higher sensitivity for the detection of phosphorylated STAT1. However, also under these conditions and in contrast to mature neutrophils, we observed no significant increases in STAT1 phosphorylation in IFN- -stimulated immature neutrophils (Fig. 5B). In conclusion, STAT1 occurs at lower levels and cannot efficiently be tyrosine-phosphorylated upon IFN stimulation in immature compared with mature neutrophils.
IFN Priming for Extracellular Trap Formation in Mature but Not Immature Human NeutrophilsTo understand the biological relevance of the observed differences between immature and mature neutrophils regarding the efficacy of IFN signal transduction, we established two functional in vitro assays. First, we investigated the effect of IFN- and IFN- , respectively, on the formation of extracellular traps in both immature and mature neutrophils. Second, we analyzed IFN effects on growth factor-induced proliferative responses in immature neutrophils.
Neutrophil extracellular traps are structurally composed of granule and nuclear constituents that disarm and kill bacteria (11). Because DNA is a major structural component of neutrophil extracellular traps, we used a propidium iodide staining procedure to make the extracellular structures visible. Priming with IFN-
Neutrophil extracellular trap formation was quantified by two ways. First, we measured the amount of released DNA using a DNA dye that is excluded from cells. Second, we analyzed the amount of released MPO, which is another major component of neutrophil extracellular traps (11). IFN- and IFN- amplified both C5a-induced DNA (Fig. 7A) and MPO (Fig. 7B) release from mature neutrophils. In contrast, immature neutrophils did not respond with a significant DNA or MPO release upon IFN- /C5a and IFN- /C5a, respectively, stimulation.
To further demonstrate that IFN signaling pathways do not operate in an efficient manner in immature neutrophils, we investigated the effects of both IFNs on G-CSF and GM-CSF-induced proliferation of these cells. Both IFN- and IFN- had only marginal effects on G-CSF- or GM-CSF-induced proliferation of immature neutrophils (Fig. 8). As a control in these assays, we used phytohemagglutinin-stimulated PBMC, which had decreased proliferative responses in the presence of IFN- (data not shown).
During a large scale survey investigating gene expression profiles in neutrophils, we obtained evidence for the induction of genes encoding receptors for antibodies, cytokines, and chemokines as well as molecules involved in signal transduction during the terminal differentiation of these cells. Among these genes we identified many molecular components of the type I and type II IFN pathways. Moreover, the mRNA expression of several of these molecules involved in IFN signaling in mature neutrophils was reduced by GM-CSF in vitro. If freshly isolated immature and mature neutrophils were compared, we noticed that the differences in gene expression of the IFN signaling components correlated with the expression of IFN-regulated genes. This pointed to the possibility that the increased levels of expression of the IFN signaling components in mature neutrophils might result in increased in vivo IFN sensitivity of mature compared with immature neutrophils.
Indeed, we obtained evidence for more efficient type I and type II IFN signal transduction in mature compared with immature cells. For instance, STAT1 was not only expressed at lower levels in immature neutrophils; it was also not phosphorylated on Tyr-701 (25) upon both IFN-
Increased IFN(s) production has been demonstrated during bacterial infections. For instance, LPS released IFN-
Because IFN-
Treatment of patients with IFN- There was only little interindividual variability regarding gene expression in immature and mature neutrophils. This suggested that the individuals from whom we obtained the bone marrow aspirates and the blood were indeed healthy. In contrast, when we mimicked the situation of an infectious disease condition by exposing mature neutrophils to GM-CSF in vitro, we observed dramatic changes in gene expression. This is in agreement with previously published work, which analyzed gene expression modification related to cancer and bacterial infection in blood leukocytes (37). Interestingly, it appears that the number of genes that are down-regulated as a consequence of GM-CSF exposure is greater than the number of induced genes. We investigated gene expression profiles between human immature bone marrow neutrophils and human mature blood neutrophils. A similar analysis in specific immature neutrophil subsets would be of great interest but is hampered by the non-availability of suitable purification techniques. Highly purified cell populations would be required to precisely detect the exact time periods of expression of individual genes. Although we used a mixture of immature neutrophils, gene expression profiles demonstrated only little variability among different donors. It is possible that the inter-individually variability is higher under in vivo pathologic conditions. Therefore, further work is required to compare gene expression pattern between normal and infectious diseases blood neutrophils (e.g. cystic fibrosis, sepsis).
* This work was supported by Swiss National Science Foundation Grants 31-68449.02 and 31-58916.99), the Bernische Krebsliga (Bern), and the Gottfried and Julia Bangerter-Rhyner Foundation (Zurich). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
** To whom correspondence should be addressed: Dept. of Pharmacology, University of Bern, Friedbühlstrasse 49, CH-3010 Bern, Switzerland. Tel.: 41-31-632-3281; Fax: 41-31-632-4992; E-mail: hus{at}pki.unibe.ch.
1 The abbreviations used are: G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte/macrophage colony-stimulating factor; C5a, complement factor 5a; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; IFN, interferon; Jak, Janus kinase; MPO, myeloperoxidase; PBMC, peripheral blood mononuclear cells; STAT, signal transducer and activator of transcription; Ab, antibody; mAb, monoclonal Ab.
We are indebted to our hematologists from the Department of Hematology, University of Bern, for diagnostic evaluation of the bone marrow aspirates. We also thank Dr. S. Christen (Institute of Infectious Diseases, Bern) for help with the MPO measurements and gratefully acknowledge the technical assistance of I. Schmid and E. Kozlowski (Department of Pharmacology, Bern).
This article has been cited by other articles:
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Advertisement | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||